

ESPS Peer-review Report

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 4517

Title: Invited Review Article Reference ID 00010717

Reviewer code: 00009860

Science editor: Zhai, Huan-Huan

Date sent for review: 2013-07-03 16:00

Date reviewed: 2013-07-14 21:30

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

COMMENTS TO AUTHORS

This is an excellent review. Almost all treatment options are described in a well-balanced way. Only the presentation of liver resection versus RFA is quite unbalanced as concerns the level of evidence. None of the four studies cited[53-56]represents a prospective, controlled double-blind study. In all 4 studies the groups of patients treated by either RFA or surgical resection are either unbalanced or the drops outs differ significantly. Only the Hongkong study by Chen et al. (Ann Surgery 2006) was designed as randomised prospective trial with balanced groups of patients. However, no difference of RFA versus resection was observed in that study. The postoperative mortality of hepatic resection was impressively low (<2%) in the 4 studies cited [53-56]. This observation argues for centralisation of liver surgery as to provide low morbidity and low surgical mortality (<3-8%) even to the everyday HCC patient that is not included in a clinical trial .